clinical trial · NCT03304418
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
Prostate Cancer Metastatic to BoneRadium Ra 223 DichlorideRadiation
brief summary
This is a phase IIa, open label, single arm, and prospective study of hormone therapy-naïve men with oligometastatic prostate cancer to the bone. The study will test if treating the primary tumor sites and 5 or fewer sites of bone-only metastasis with external beam radiation with concomitant systemic Radium-223 will reduce the utilization of androgen deprivation therapy, improve QOL and improve OS over a the comparator cohort of SWOG intermittent ADT historic cohort.
started
Feb 27, 2018
primary completion
Sep 30, 2022
completion
Aug 31, 2023
last updated
Apr 30, 2025
official title
A Phase 2 Study of Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol